Hemodialysis Vascular Grafts Market – By Product Type, By Material, By End Use – Global Forecast, 2025 – 2034

Hemodialysis Vascular Grafts Market Size

The global hemodialysis vascular grafts market size was valued at USD 245.8 million in 2024 and is projected to exhibit 5% CAGR from 2025-2034. Hemodialysis vascular grafts are the medical devices created to facilitate vascular access in patients undergoing hemodialysis, especially those with end stage renal disease (ESRD) and do not qualify for arteriovenous fistulas.
 

The global burden of end-stage renal disease continues to increase due to diabetes, hypertension, and aging populations, resulting in more patients requiring long-term hemodialysis. According to the World Health Organization (WHO), approximately 850 million people worldwide have kidney diseases from various causes. This expanding patient population increases the demand for vascular grafts, which provide reliable and durable vascular access for individuals unsuitable for arteriovenous fistulas, indicating a sustained need for advanced vascular access solutions.
 

Additionally, innovations in graft technology, including bioengineered and hybrid materials, improve the durability, flexibility, and biocompatibility of hemodialysis vascular grafts. These advancements result in fewer complications, extended graft patency, and increased clinical adoption across developed and emerging healthcare markets, suggesting continued investment in graft technology research and development.
 

The rising prevalence of chronic kidney disease (CKD) and ESRD correlates with global population aging. According to the 2023 study published by Elsevier Journal, CKD is common, affecting 11% of the adult population globally; the prevalence rises sharply with age. Elderly patients frequently require synthetic or biological vascular grafts instead of fistulas due to limited vascular access options. This demographic trend sustains the demand for graft-based dialysis access solutions, highlighting the growing importance of age-appropriate vascular access strategies.
 

The growth of dialysis centers in low- and middle-income countries, along with improved healthcare service access, increases vascular graft utilization. Government initiatives and increased renal care investment enhance the accessibility and affordability of advanced graft technologies, enabling broader access to regular hemodialysis, emphasizing the need for continued expansion of renal care infrastructure worldwide.
 

Hemodialysis Vascular Grafts Market Trends

• The market depicts growing acceptance of bioengineered and hybrid vascular grafts blending synthetic and natural materials. They minimize infection and thrombosis risk while maximizing long-term patency.
• The technology responds to clinical need for physiologically compatible access modes, especially among patients with constrained vein availability or high complication threat.
   
• Physicians favor those graft solutions that enable minimally invasive placement procedures. This is since there are pressures to reduce procedure time, minimize patient pain, and minimize surgical complications.
• Companies currently aim to produce products that help facilitate percutaneous or less invasive grafting implantation, in line with the expansion of outpatient and ambulatory care.
   
• Coated grafts have antimicrobial and anti-thrombogenic surface technologies from manufacturers to improve patency and reduce post-implantation complications.
   
• The coatings prevent infections, clotting, and premature failure of the graft, which are matters of considerable concern in chronic hemodialysis patients. Increased focus on reducing infection-related hospitalization is driving the application of coated grafts in clinical practices and procurement practices.
   
• Market players are expanding into emerging markets such as Asia-Pacific, Latin America, and the Middle East and Africa due to growing numbers of cases of chronic kidney disease and healthcare spending infrastructure establishment.
   
• Firms invest in local manufacturing, distribution alliances, and government procurement initiatives to establish market presence, promoting cost-effective graft solutions for large numbers of dialysis patients.
   

Hemodialysis Vascular Grafts Market Analysis

Based on product type, the market is bifurcated into synthetic and biological. The synthetic segment dominated the market with the largest revenue share of 86.1% in 2024.
 

• Synthetic hemodialysis grafts are advantageous as they can be used straight away in comparison to weeks of maturation required by arteriovenous fistulas. Synthetic grafts are necessary for acute or emergent dialysis indications, due to their immediate availability.
   
• The increasing need for emergency hemodialysis access, especially within the hospital and emergency settings, makes it a desirable alternative for their biological counterparts.
   
• In addition, synthetic material technologies such as expanded polytetrafluoroethylene (ePTFE) and polyurethane improve vascular graft performance, flexibility, and durability. Thrombosis and risk of infection is minimized with surface treatment and heparin-bonded coatings.
   
• These developments make clinical efficacy of the synthetic grafts and long-term patency to justify their increasing use in dialysis therapy programs.
   

Based on material, the hemodialysis vascular grafts market is segmented into polytetrafluoroethylene (PTFE), polyurethane, polyester, biological, and hybrid. The polytetrafluoroethylene (PTFE) segment dominated the market with the largest revenue of USD 162.5 million in 2024.
 

• PTFE grafts are preferred in hemodialysis application due to their biocompatibility, which inhibits immune responses and ensures longer application among patients. Chemical stability and surface non-reactivity reduce the risk of graft rejection, making them essential in chronic dialysis therapy.
   
• In addition, PTFE grafts have stable long-term vascular access function due to their reliability and rates of long-term patency. These attributes allow repeated needle punctures in continuous hemodialysis treatments.
   
• Further, PTFE grafts offers clinical advantages in terms of ease of suturing, handling, and implantation in vascular surgery. They are flexible and retain their shape, making it simpler to place and reducing procedure time. Such aspects enhance their worth in dialysis centers and theatres where efficiency of operation and safety of patients is paramount.

Based on end use, the hemodialysis vascular grafts market is segmented into hospitals, ambulatory surgical centers, dialysis centers, and other end users. The dialysis centers segment dominated the market with a share of 46.1% in 2024.
 

• The worldwide growth of chronic kidney disease and end-stage renal disease cases has fueled swift growth of dialysis facilities. As per the National Kidney Foundation, among individuals aged 65-74 years, an estimated one out of five males and one out of four females suffer from CKD across the world.
   
• The addition of new facilities to house these increasing patient counts directly raises the demand for vascular access solutions, such as hemodialysis grafts across dialysis centers, driving the revenue growth in the segment.
   
• High-volume dialysis centers need effective vascular access solutions for treating patients. Hemodialysis grafts, especially synthetic types, have shorter maturation times than arteriovenous fistulas, allowing quicker deployment. This functional benefit encourages dialysis centers to have frequent inventory and utilization of graft products, further aiding to the segment’s growth.

North America leads the hemodialysis vascular grafts market with a revenue of USD 105.7 million in 2023, that increased to USD 109.9 million in 2024. The market is expected to grow with a CAGR of 4.9% during the forecast period. The revenue growth can be attributed to the high end-stage renal disease (ESRD) cases, a strong healthcare infrastructure supporting hemodialysis services, and effective reimbursement policies.
 

The U.S. market is projected to grow significantly from USD 99 million in 2024 to USD 159.4 million by 2034.
 

• The U.S. has a high rate of diabetes and hypertension, both leading causes of chronic kidney disease and end-stage renal disease. For instance, according to the American Diabetes Association, 1.2 million U.S. residents are diagnosed with diabetes every year.
   
• In addition, as per National Institutes of Health, chronic kidney disease affects one in seven adults, estimating to about 35.5 million adults in the U.S. The development of these diseases expands the number of patients needing long-term dialysis, fueling the demand for vascular access solutions in the country.
   
• Medicare and other federal healthcare programs offer comprehensive coverage of dialysis treatments and vascular access procedures. This payment arrangement makes hemodialysis grafts widely available to patients and incentivizes healthcare providers to use sophisticated vascular access technologies.
   
• The public insurance scheme established in the U.S. provides a solid platform for growth in the market for hemodialysis graft.
   

Europe hemodialysis vascular grafts market is expected to value at USD 97.4 million by 2034.
 

• Europe accounts for a prominent portion of the global market due to the elderly population, increasing chronic kidney disease (CKD) cases, as well as the existence of universal healthcare systems.
   
• Countries such as Germany, UK, and France have a well-structured dialysis network along with raised levels of awareness regarding vascular access best practices.
   
• In addition, the adoption of biocompatible materials and collaboration between medical technology companies and hospitals fuel market growth across the region. Strong regulatory frameworks aid support the entire region.
   

The hemodialysis vascular grafts market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• There are increasing numbers of end-stage renal disease (ESRD) and chronic kidney disease (CKD) cases in the UK owing to its aging population, and higher diabetes, obesity, and hypertension prevalence. According to Kidney Research UK, approximately 3.25 million adults have chronic kidney disease stages 3-5, and 7.2 million adults have chronic kidney disease (all stages), which estimates to more than 10% of the population.
   
• The increasing number of patients in need of dialysis is driving the demand for vascular access solutions, such as hemodialysis grafts, especially among patients who are not suitable for fistulas because of age-related vascular complications. This trend reflects a continued demand for sophisticated vascular access solutions within the UK healthcare system.
   
• The National Health Service (NHS) is increasing its dialysis capacity in hospital-based and satellite units throughout the UK. This growth requires stable vascular access solutions, such as synthetic and bioengineered grafts. Growing emphasis on early intervention and accessibility of CKD care reflects the prospect for vascular graft usage growth together with increased availability of treatment, ensuring revenue growth in the market.
   

Asia Pacific is expected to witness lucrative growth opportunities in the hemodialysis vascular grafts market during the forecast period.
 

• Asia-Pacific region is expected to remain the fastest growing markets for hemodialysis vascular grafts owing to the surging diabetes and hypertension burden which are major drivers of chronic kidney disease (CKD) and end-stage renal disease (ESRD). According to the 2024 study published by Journal of Asian Pacific Society of Cardiology, Asia-Pacific region has an approximate prevalence of hypertension between 10.6% and 48.3%.
   
• China, India, and other countries in Southeast Asia are experiencing rapid enhancement of healthcare infrastructure, which has improved the availability of healthcare services, including access to dialysis treatments. This has contributed to higher demand for hemodialysis vascular grafts across the region.
   
• Increased healthcare spending, vascular kidney care initiatives by the government, and enhanced spending from both regional and international players are also driving the adoption of vascular grafts in the region.
   

Japan hemodialysis vascular grafts market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Aging population in Japan has caused a rise in elderly dialysis patients with weak vascular systems. As per the Japanese Society for Dialysis Therapy, in the year 2020, an estimated 347,671 patients undergo dialysis treatment in Japan, of whom more than 65% are 65 and older. These patients typically are not able to use arteriovenous fistulas, so artificial hemodialysis grafts become a requirement for their treatment.
   
• Japan's national healthcare system provides broad coverage for dialysis therapy and procedures in support of the adoption of advanced vascular access technologies.
   
• The national payment system permits the use of hemodialysis vascular grafts that are proven to have long-term safety and patency, enabling dialysis facilities and hospitals to include the grafts in routine care for patients who have complex access requirements.
   

Brazil is experiencing significant growth in the Latin America hemodialysis vascular grafts market due to its high volume of CKD cases, in conjunction with country’s public dialysis program supported by Universal Health System (SUS).
 

• The country's public healthcare system, Sistema Único de Saúde (SUS), as of a July 2024 study by the National Center for Biotechnology Information, covers 79% of dialysis treatments nationwide. This ensures access to care, including vascular access procedures utilizing artificial grafts.
   
• In addition, cities such as São Paulo, Rio de Janeiro, and Belo Horizonte in Brazil have high density of dialysis centers and specialized care in nephrology which assists the adoption of developed graft technologies, further aiding to the market growth.
   

The Saudi Arabia hemodialysis vascular grafts market is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia boasts one of the highest rates of hypertension and diabetes in the Middle East. The increasing age group and prevalence of lifestyle diseases are expected to drive steady demand for dialysis treatment and vascular access products like hemodialysis grafts. This trend is consistent with the rising demand for specialized vascular access therapy at Saudi healthcare facilities.
   
• The Saudi Vision 2030 healthcare initiatives include significant investment in the growth of dialysis center healthcare infrastructure, particularly that of vascular access technologies such as synthetic and hybrid grafts. Increased use of newer technologies such as these vascular access technologies is facilitated by this infrastructure development.
   
• The new building expansions in urban and rural areas are increasing the need for reliable, standardized dialysis access solutions.
   

Hemodialysis Vascular Grafts Market Share

The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced devices for the growing patient population. Companies such as W. L. Gore & Associates, Becton Dickinson and Company, Terumo Medical, Merit Medical Systems, and Getinge AB are some of the dominant competitors in the market accounting for a combined market share of approximately 60%. Competition in this area arises from continuous technological developments and the ability to offer customized solutions.
 

In developing nations, due to the priority given to cost, multinational companies are squeezed to offer hemodialysis vascular grafts that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Hemodialysis Vascular Grafts Market Companies

Some of the eminent market participants operating in the hemodialysis vascular grafts industry include:

• Artivion
• Becton Dickinson and Company
• BIOVIC
• Cook Medical
• CryoLife
• Getinge
• Laminate Medical Technologies
• LeMaitre
• Merit Medical Systems
• ParaGen Technologies
• Proteon Therapeutics
• Terumo Medical
• Vascudyne
• Vascular Genesis
• W L Gore & Associates
   
• W. L. Gore & Associates is one of the key market player that offers advanced  hemodialysis vascular grafts such as GORE-TEX Vascular Grafts, a commonly used PTFE grafts across the globe. The products exhibit long-term stability, low thrombogenicity, and excellent surgical handling properties. The grafts include reinforcement for resistance to kinking and burst strength, necessary in high-flow dialysis usage.
   
• Becton Dickinson and Company pioneers through offering VENATECH polyurethane grafts that features greater flexibility and kink resistance than traditional PTFE options, especially useful for difficult patient anatomies. The product has infection-resistant coatings and reduced needle-hole bleeding. BD combines these grafts into its total vascular access product portfolio, including dialysis catheters and fistula solutions, through its well-established interventional nephrology distribution channel.
   
• Terumo combines Japanese engineering with American clinical know-how to develop grafts with strong anastomotic properties and effective pulsatile flow performance. Terumo provides end-to-end vascular access solutions, including imaging and surgical equipment. Its Flixene Vascular Graft is a tapered PTFE configuration that enhances hemodynamics and minimizes intimal hyperplasia.
   

Hemodialysis Vascular Grafts Industry News:

• In May 2025, Merit Medical Systems, a leading global healthcare technology company, announced the regulatory clearance of Wrapsody Cell-Impermeable Endoprosthesis (CIE) from Health Canada. The company intends to initiate commercialization of the device throughout Canada, that can be distributed from its Toronto hub. The achievement increased Merit's presence in the global market and helped fuel growth within its vascular access business segment.
   
• In January 2025, W. L. Gore & Associates, Inc. (Gore) announced the FDA clearance of a reduced profile GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) as part of its initiative to promote treatment options for patients with advanced vascular disease. The clearance added to Gore's endovascular product line and solidified its commitment to providing innovative, less invasive treatment solutions.
   
• In December 2024, Merit Medical Systems announced that the Wrapsody cell-impermeable endoprosthesis was granted premarket approval by the FDA. The Wrapsody device is a self-expanding, flexible endoprosthesis for hemodialysis patients for the management of stenosis or occlusion in the dialysis access outflow circuit. This clearance solidified the company's vascular access offering and further established its competitiveness in the hemodialysis marketplace.
   
• In August 2022, W. L. Gore & Associates, a global leader in material science, announced the acquisition of privately owned medical technology firm InnAVasc Medical, with a focus on innovation in the treatment of patients with end-stage renal disease using graft circuits to perform dialysis. The action strengthened company’s market position in the dialysis access segment and brought the company's portfolio of innovative vascular access solutions to the fold.
   

The hemodialysis vascular grafts market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product Type

• Synthetic
• Biological

By Material

• Polytetrafluoroethylene (PTFE)
• Polyurethane
• Polyester
• Biological
• Hybrid

By End Use

• Hospitals
• Ambulatory surgical centers
• Dialysis centers
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE